As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Read More
Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
Read More
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Read More
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
Read More
Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction…
Read More
Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join…
Read More
